Arjen M. DondorpN. P J DayMahidol UniversityJohn Radcliffe Hospital2018-08-242018-08-242007-07-01Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.101, No.7 (2007), 633-634003592032-s2.0-34248142148https://repository.li.mahidol.ac.th/handle/20.500.14594/24531In the SEAQUAMAT trial, parenteral artesunate was shown to be associated with a considerably lower mortality than quinine, and is now the recommended treatment for severe malaria in low-transmission areas and in the second and third trimesters of pregnancy. A trial is underway to establish its role in African children. The development of artesunate suppositories may provide the means to treat patients with severe disease in remote rural settings, potentially buying the time needed to reach a health care facility. The increasing availability of basic intensive care facilities in developing countries also has the potential to further reduce mortality. © 2007 Royal Society of Tropical Medicine and Hygiene.Mahidol UniversityImmunology and MicrobiologyMedicineReviewSCOPUS10.1016/j.trstmh.2007.03.011